High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.
Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, Huber V, Maio M, Rivoltini L, Fais S. · 2009
Read High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. by Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, Huber V, Maio M, Rivoltini L, Fais S. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2667632.txt.
Introduction
Logozzi and colleagues reported in 2009 that the blood of melanoma patients carries far more tiny tumor-linked parcels than the blood of healthy people. The parcels, called exosomes, are shed by normal and cancer cells alike. Melanoma that has spread is incurable, and doctors lack a simple blood marker to track it.
The team built a lab test that catches exosomes using two common parcel proteins, then counts a second set marked with caveolin-1, a protein tied to tumors. In mice carrying human melanoma, parcel levels rose with tumor size. In 90 patients and 58 healthy donors, both parcel types were much higher in patients. The caveolin-1 test caught about 68 percent of patients, the better of the two. Tuning this blood test, the authors suggest, could give a needle-free way to screen and follow the disease.
Catalog record
| CREATOR | Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, Huber V, Maio M, Rivoltini L, Fais S. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients By Mariantonia Logozzi, Angelo De Milito, Luana Lugini, Martina Borghi, Luana Calabrò, Massimo Spada, Maurizio Perdicchio, Maria Lucia Marino, Cristina Federici, Elisabetta Iessi, Daria Brambilla, Giulietta Venturi Published in: PLoS ONE DOI: 10.1371/journal.pone.0005219 ABSTRACT Abstract Background Metastatic melanoma is an untreatable cancer lacking reliable and non-invasive markers of disease progression. Exosomes are small vesicles secreted by normal as well as tumor cells. Human tumor-derived exosomes are involved in malignant progression and we evaluated the presence of exosomes in plasma of melanoma patients as a potential tool for cancer screening and follow-up. Methodology/Principal Findings We designed an in-house sandwich ELISA (Exotest) to capture and quantify exosomes in plasma based on expression of housekeeping proteins (CD63 and Rab-5b) and a tumor-associated marker (caveolin-1). Western blot and flow cytometry analysis of exosomes were used to confirm the Exotest-based findings. The Exotest allowed sensitive detection and quantification of exosomes purified from human tumor cell culture supernatants and plasma from SCID mice engrafted with human melanoma. Plasma levels of exosomes in melanoma-engrafted SCID mice correlated to tumor size. We evaluated the levels of plasma exosomes expressing CD63 and caveolin-1 in melanoma patients (n = 90) and healthy donors (n = 58). Consistently, plasma exosomes expressing CD63 (504±315) or caveolin-1 (619±310) were significantly increased in melanoma patients as compared to healthy donors (223±125 and 228±102, respectively). While the Exotest for CD63+ plasma exosomes had limited sensitivity (43%) the Exotest for detection of caveolin-1+ plasma exosomes showed a higher sensitivity (68%). Moreover, caveolin-1+ plasma exosomes were significantly increased with respect to CD63+ exosomes in the patients group. Conclusions/Significance We describe a new non-invasive assay allowing detection and quantification of human exosomes in plasma of melanoma patients. Our results suggest that the Exotest for detection of plasma exosomes carrying tumor-associated antigens may represent a novel tool for clinical management of cancer patients. INTRODUCTION Exosomes are small endosome-derived vesicles (50–100 nm in size), actively secreted through an exocytosis pathway normally used for receptor discharge and intercellular cross-talk [1]–[3]. In addition to major histocompatibility complex proteins (MHC I, MHC II) and proteins involved in antigen presentation, exosomes may carry membrane and cytosolic proteins involved in many cellular functions [1], [4]. These structures are secreted under specific physiological conditions from different cell types such as dendritic cells (DC), lymphocytes, mast cells and epithelial cells [5]–[8]. However, release of exosomes from tumor cells is dramatically increased and represents a constitutive process, often associated with immunosuppressive effects [3], [9], [10]. The role of tumor exosomes in cancer progression is recently emerging, although initial data pointing at these organelles as carriers of tumor antigenic material for DC-mediated T cell cross-priming have supported clinical attempts to use tumor exosomes as anti-cancer vaccines [11]. However, growing evidence concerning a vast array of suppressive effects exerted by these microvesicles on different components of the immune system is clearly supporting the involvement of tumor exosomes in disease progression [3], [12]. In particular, we and others have recently shown that exosomes secreted by human tumor cells of various origins are able to induce apoptosis in activated T cells, through the expression of death ligands (e.g. FasL, TRAIL) [9], [10], [13], inhibit NK functions [14], [15] and promote the generation of myeloid-derived suppressor cells from normal monocytes [10]. These data, together with the reproducible evidence that exosomes of likely tumor origin can be abundantly found in plasma and neoplastic effusions of cancer patients [16]–[18] support a role of tumor exosomes in molding host microenvironment to allow tumor growth and progression [19], [20]. However, the study of the in vivo role of tumor exosomes has been so far penalized by the lack of suitable methods to quantify exosomes from human body fluids, particularly from plasma of cancer patients. The aim of our study was thus to provide a method to detect and quantify exosomes from small amount of human plasma, with the final goal of identifying a tool for assessing the role of tumor exosomes as potential tumor marker and prognostic factor. This might be particularly relevant in melanoma patients, in which sensitive and reliable serum markers are unfortunately still limited while serum LDH (lactate dehydrogenase) levels remain the only prognostic serum factor for assessing disease course and prognosis [21], [22]. Here, we describe an in-house ELISA that allows quantification and characterization of exosomes from different samples, including plasma from tumor-bearing animals and melanoma patients, as well as from tumor cell culture supernatants. These findings suggest that the detection of tumor exosomes in plasma of cancer patients may represent a potential biomarker in the clinical monitoring of tumor malignancies, in particular melanoma. RESULTS Set up of in-house ELISA for exosomes quantification Exosomes detection in vitro The ELISA we developed is based on the presence on exosome of proteins shared with cytoplasmic organelles such as endosomes and lysosomes (Rab-5b and CD63), whose membranes are not shed or recycled as for plasma membrane structures, thus excluding the possible presence of structures deriving from membranes shedding and disruption [23]. Culture supernatants of melanoma cells Me501 and MeBS were processed to obtain purified exosomes and data are shown for Me501 cells. The Exotest (Figure 1A) was able to provide a quantification of the exosomes present in cell culture supernatants, being CD63+ exosomes detectable in a dose-dependent manner (Figure 1B). The negative controls, represented by fractions derived from pellet obtained after the 10000 g centrifugation, exosomes purified from cell culture medium alone and by the only secondary antibody resulted in a barely measurable optical density (OD = 0.07±0.01). Intra and inter-test variability were calculated on six replicates of the same preparation run on three different plates and were 30% and 25%, respectively. A patent application has been recently registered for this in-house ELISA (#US 12/321,412; PCT/EE2009/000001) and the Exotest is currently being standardized to reach variability comparable to commercially available kits (HansaBiomed, O.U., Estonia). Western blot and FACS analysis of the same purified exosome preparations confirmed the data obtained by Exotest. In fact, Rab-5b, Lamp-1 and to a lesser extent CD63 proteins were detectable by WB (Figure 1C) and both Rab-5b and CD63 were also detected by FACS on exosomes bound to latex beads (Figure 1D). However, exosomes detection and quantification by Exotest showed a higher sensitivity for the detection of CD63 protein with respect to WB analysis (Figure 1C). Indeed, while at least 12.5 µg of exosome proteins were needed to properly detect both CD63 and Rab-5b by WB, the Exotest was able to detect exosomes starting from a minimum amount of 3 µg of purified samples. [Figure: Detection of exosomes purified from cell culture supernatants of human melanoma cells.(A) Schematic representation of the ELISA (Exotest) set up for exosomes detection and quantification. (B) Dose-escalation analysis of purified CD63+ exosomes by Exotest. The initial concentration corresponded to 50 µg of exosomes and exosomes were added in two-fold dilutions. (C) Western blot analysis of CD63, Rab-5b and Lamp-1 expression in different amount of exosomes purified from culture supernatants of human melanoma cells (Me501). (D) FACS analysis of Rab-5b and CD63 expression on melanoma-derived exosomes purified from the supernatant of Me501 cells and coated to latex beads.] Plasma exosomes in SCID mice engrafted with